Advertisement

Topics

Search Results for "Xarelto Vs Pradaxa"

16:35 EDT 30th April 2017 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Bristol-Myers and Pfizer's Eliquis outperforms rivals versus warfarin

In a so-called real world study, the anti-coagulant did better in reducing the risk of strokes or major bleeds compared to warfarin than did J&J's competing Xarelto or Boehringer's&nb...

Pradaxa Beats Warfarin After Heart Rhythm Procedure: Study

MONDAY, March 20, 2017 -- Patients undergoing a surgical procedure to treat an irregular heartbeat are less likely to suffer problematic bleeding when given the blood thinner Pradaxa rather than warfa...

Bayer’s Xarelto beats aspirin in preventing blood clots

Data from a late-stage trial show that Bayer and Janssen’s Xarelto was better than aspirin at protecting patients from recurrent venous thromboembolism.

Heart trial success will give Xarelto edge

Janssen and Bayer have stopped a phase 3 trial of Xarelto early after results showed it can cut deaths, heart attacks and strokes compared to aspirin. The promising data paves the way for a lucrativ...

STAT Plus: Japanese government probes Bayer over Xarelto medical papers

A former Bayer sales rep says he was forced to gather patient data that was used to prepare medical journal papers for promoting the Xarelto blood thinner.

Phase III COMPASS study of Xarelto stopping early for ‘overwhelming efficacy’

The Phase III trial COMPASS evaluating the efficacy and safety of Xarelto (rivaroxaban) for the prevention…

Boehringer Ingelheim Presents Real-world Analysis of Pradaxa Users

NewsPharmaceutical company Boehringer Ingelheim Pharmaceuticals Inc., presented two studies at the American Society of Hematology Annual Meeting in San Diego, which showed patients who were newly diag...

Bayer’s cardiovascular drug races to target in trial

Bayer has been putting its blood-thinning drug, Xarelto, through its paces in a Phase 3 trial to determine whether it could help patients at risk from heart attacks and strokes due to a type of artery...

Matching PubMed Articles

Caution When Prescribing Xarelto to First-Time Patients.

Drug interaction: dabigatran (Pradaxa) and statins.

Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review.

Direct oral anticoagulants (DOACs) are in wide use among patients requiring both short- and long-term anticoagulation, mainly due to their ease of use and the lack of monitoring requirements. With gro...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement